New corona vaccine: Novavax reports 100 percent protection against severe courses
6 a.m., March 13, 2021
Of the Corona vaccine from the US company Novavax has one in studies one hundred percent effectiveness against severe courses shown by Covid-19. Against mild and moderate courses, especially the South African variant however, if the effectiveness is significantly less good, the company announced on Thursday (local time). The vaccine is a dead vaccine that uses the spike protein of the coronavirus to induce the formation of antibodies.
As part of a Phase 3 study In the UK, the active ingredient had been tested on 15,000 people between 18 and 84 years, the company announced. The effectiveness against light, moderate and severe courses of the conventional variant of the virus is therefore included 96.4 percent. Against the British mutant of the virus the effectiveness is included 89.7 percent.
In South Africa the company tested the vaccine in a Phase 2 study to around 2600 people. The effectiveness of only 48.6 percent located that in HIV-negative people it was 55.4 percent. In both studies, however, the vaccine showed one hundred percent protection against severe courses. The Maryland-based company said it intends to apply for approval for the vaccine first in the UK and then in the US in early April.